These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26243782)
1. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Evans M; Suttorp MM; Bellocco R; Hoekstra T; Qureshi AR; Dekker FW; Carrero JJ Nephrol Dial Transplant; 2016 Apr; 31(4):628-35. PubMed ID: 26243782 [TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
3. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198 [TBL] [Abstract][Full Text] [Related]
4. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses. Rao A; Gilg J; Williams A Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174 [TBL] [Abstract][Full Text] [Related]
5. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195 [TBL] [Abstract][Full Text] [Related]
6. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469 [TBL] [Abstract][Full Text] [Related]
7. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Macdougall IC Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980 [TBL] [Abstract][Full Text] [Related]
8. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375 [TBL] [Abstract][Full Text] [Related]
9. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Evans M; Bower H; Cockburn E; Jacobson SH; Barany P; Carrero JJ Clin Kidney J; 2020 Oct; 13(5):821-827. PubMed ID: 33123358 [TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350 [TBL] [Abstract][Full Text] [Related]
11. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort. Yong K; Kairaitis L Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296 [TBL] [Abstract][Full Text] [Related]
12. Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. Gardiner R; Roshan D; Brennan A; Connolly D; Murray S; Reddan D Ir J Med Sci; 2019 Feb; 188(1):223-230. PubMed ID: 29704093 [TBL] [Abstract][Full Text] [Related]
13. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218 [TBL] [Abstract][Full Text] [Related]
14. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376 [TBL] [Abstract][Full Text] [Related]
15. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease. Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003 [TBL] [Abstract][Full Text] [Related]
16. A retrospective database analysis of erythropoiesis-stimulating agent treatment patterns and associated healthcare resource use in patients with non-dialysis-dependent chronic kidney disease-related anaemia in Japan. Mishina S; Waratani M; Onozawa S; Okumura H; Ito Y; Yasuda Y Nephrology (Carlton); 2023 Aug; 28(8):446-455. PubMed ID: 37161826 [TBL] [Abstract][Full Text] [Related]
17. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587 [TBL] [Abstract][Full Text] [Related]